GPC3 CAR-T therapy (Hrain Biotechnology)

N/A

Report date: 2022/10/25 17:50:03

Base Information

Drug NameGPC3 CAR-T therapy (Hrain Biotechnology)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionGlypican-3 inhibitorsWnt signalling pathway inhibitors

TargetsGlypican-3

Therapy Area/IndicationsCarcinoma, Hepatocellular

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesHrain Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesThe Second Affiliated Hospital of Army Medical University

Inactive CompaniesN/A

Active IndicationsCarcinoma, Hepatocellular

Inactive IndicationsN/A

Other Information

ATC CodeN/A